In:
eJHaem, Wiley, Vol. 3, No. 1 ( 2022-02), p. 231-234
Abstract:
Chimeric antigen receptor (CAR) T‐cell therapy represents a new strategy in treating lymphoid malignancies, such as relapsed‐refractory diffuse large B‐cell lymphoma (DLBCL). Several toxicities including cytokine release syndrome (CRS), neurotoxicity, and cardiovascular toxicity have been linked to CAR T‐cell therapy. Transient impairment in left ventricular systolic function is described after CAR‐T, however, the mechanism remains poorly understood. This paper reports the clinical presentation and outcome of two patients with relapsed‐refractory DLBCL who experienced encephalopathy and CRS following CAR T‐cell therapy and developed transient left ventricular dysfunction consistent with stress cardiomyopathy.
Type of Medium:
Online Resource
ISSN:
2688-6146
,
2688-6146
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
3021452-X